Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abbott LaboratoriesXSWX:ABT 80 Earnings Yield (Joel Greenblatt) % is 4.15% as of Mar. 2026, which is 26% above its 10-year median of 3.30. GuruFocus rates XSWX:ABT with a GF Score™ of 80/100 and a GF Value™ of CHF107.71. Among 852 Medical Devices & Instruments companies, Abbott Laboratories ranks better than 64.79% on this metric.
Abbott Laboratories's Enterprise Value for the quarter that ended in Mar. 2026 was CHF165,265 Mil.
Abbott Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was CHF6,458 Mil. Abbott Laboratories's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 4.15%.
The historical rank and industry rank for Abbott Laboratories's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
XSWX:ABT'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 1.93 Med: 3.3 Max: 5.7
Current: 4.04
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Abbott Laboratories was 5.70%. The lowest was 1.93%. And the median was 3.30%.
XSWX:ABT's Earnings Yield (Joel Greenblatt) % is ranked better than 64.79% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 0.805
vs XSWX:ABT: 4.04
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Abbott Laboratories's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 2.92%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Abbott Laboratories Earnings Yield (Joel Greenblatt) % Related Terms
Abbott Laboratories Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Abbott Laboratories's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Abbott Laboratories's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbott Laboratories Earnings Yield (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Abbott Laboratories's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Abbott Laboratories's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Abbott Laboratoriess Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Abbott Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF6,458 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 4.15% mean?
Abbott Laboratories (XSWX:ABT) has a Earnings Yield (Joel Greenblatt) % of 4.15% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Abbott Laboratories and its competitors. This is 26% above median its historical median of 3.30. Over the past decade, Abbott Laboratories' Earnings Yield (Joel Greenblatt) % has ranged from 1.93 to 5.70. According to the industry distribution chart, Abbott Laboratories ranks #300 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 35.2%.
Is Abbott Laboratories' Earnings Yield (Joel Greenblatt) % too high?
Abbott Laboratories' current Earnings Yield (Joel Greenblatt) % of 4.15% is 26% above median its 10-year median of 3.30. Over the past 10 years, this metric has ranged from a low of 1.93 to a high of 5.70. The Medical Devices & Instruments industry median Earnings Yield (Joel Greenblatt) % is 0.81. Abbott Laboratories' value of 4.15% is 415.5% above this industry median. Based on the distribution chart, Abbott Laboratories ranks #300 out of 852 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Abbott Laboratories has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories' Earnings Yield (Joel Greenblatt) % compare to SYK and MDT?
According to the Medical Devices & Instruments industry distribution chart, Abbott Laboratories ranks #300 out of 852 companies for Earnings Yield (Joel Greenblatt) %. This puts Abbott Laboratories in the upper half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 0.81. Abbott Laboratories' value of 4.15% is 415.5% above this benchmark. Historically, Abbott Laboratories' own Earnings Yield (Joel Greenblatt) % has ranged from 1.93 to 5.70 over the past decade. While the company's 10-year median is 3.30 vs. the industry median of 0.81, Abbott Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median Earnings Yield (Joel Greenblatt) % among Medical Devices & Instruments companies is 0.81, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abbott Laboratories's current Earnings Yield (Joel Greenblatt) % of 4.15% is 415.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Abbott Laboratories and its competitors. For the Medical Devices & Instruments industry, the median Earnings Yield (Joel Greenblatt) % is 0.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbott Laboratories's current Earnings Yield (Joel Greenblatt) % is 4.15%, which is 26% above median its own 10-year median of 3.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories stock overvalued right now?
Abbott Laboratories (XSWX:ABT) has a current Earnings Yield (Joel Greenblatt) % of 4.15%. The stock's GF Value™ is CHF107.71, compared to a current price of CHF82.00 — trading 23.9% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 4.15%, which is 26% above median its 10-year median of 3.30 and 415.5% above the Medical Devices & Instruments industry median of 0.81. Abbott Laboratories' overall GF Score™ is 80/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Abbott Laboratories (XSWX:ABT), the current Earnings Yield (Joel Greenblatt) % is 4.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott Laboratories (XSWX:ABT) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued.
The current stock price of CHF82.00 is trading 23.9% below its estimated GF Value™ of CHF107.71.
Key valuation signals for XSWX:ABT:
Earnings Yield (Joel Greenblatt) %: 4.15% (26% above median its 10-year median of 3.30)
GF Value™: CHF107.71 vs. price of CHF82.00 (23.9% below fair value)
Industry Position: 415.5% above the Medical Devices & Instruments median (#300 of 852)
No single metric tells the full story. See the XSWX:ABT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
80GF Score
Get the complete analysis for XSWX:ABT
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ABT has been successfully added to your 
